GLENMARK: Branded growth and specialty launches underpin H2 leverage and the FY27 cash outlook

Q2 core revenue grew 20% YoY, with adjusted PAT of INR 485 crore and a 21% core EBITDA margin. Management expects H2 operating leverage, INR 700–800 crore cash generation, and gross debt repayment by FY27-end.

Based on Glenmark Pharmaceuticals Limited [GLENMARK] Q2 26/27 Audio Transcript — Nov. 6 2026